Hormonal
Higher levels of even-chain saturated fatty acids (myristic, palmitic, and stearic acid) in plasma phospholipids are positively associated with an increased risk of incident type 2 diabetes, whereas higher levels of odd-chain (pentadecanoic, heptadecanoic) and long-chain (arachidic, behenic, tricosanoic, lignoceric) saturated fatty acids are inversely associated with type 2 diabetes risk.
Stop treating all saturated fats as the same enemy. The type of fat matters significantly for diabetes risk. High levels of even-chain fats (like palmitic and stearic acid, often linked to processed foods and animal fats) are associated with higher diabetes risk. Conversely, odd-chain fats (like pentadecanoic and heptadecanoic acid, biomarkers for dairy fat) and long-chain fats are associated with lower risk. Focus on the quality and source of your fats rather than just minimizing total saturated fat intake.
Even-chain SFAs that were measured (14:0 [myristic acid], 16:0 [palmitic acid], and 18:0 [stearic acid]) were positively associated with incident type 2 diabetes... By contrast, measured odd-chain SFAs (15:0 [pentadecanoic acid] and 17:0 [heptadecanoic acid]) were inversely associated with incident type 2 diabetes... as were measured longer-chain SFAs (20:0 [arachidic acid], 22:0 [behenic acid], 23:0 [tricosanoic acid], and 24:0 [lignoceric acid])
Why this rating
Large-scale prospective case-cohort study (EPIC-InterAct) with 12,132 incident cases and objective biomarker measurement (gas chromatography) minimizes recall bias.
Source
Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study
Nita G. Forouhi et al. · The Lancet Diabetes & Endocrinology · 2014
DOI 10.1016/s2213-8587(14)70146-9
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →